Search hospitals > Wisconsin > Waukesha
ProHealth Waukesha Memorial Hospital
Claim this profileWaukesha, Wisconsin 53188
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Recurrence
Conducts research for Adenocarcinoma
217 reported clinical trials
2 medical researchers
Summary
ProHealth Waukesha Memorial Hospital is a medical facility located in Waukesha, Wisconsin. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Recurrence, Adenocarcinoma and other specialties. ProHealth Waukesha Memorial Hospital is involved with conducting 217 clinical trials across 300 conditions. There are 2 research doctors associated with this hospital, such as Timothy Wassenaar, MD and Wingate F. Clapper.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Lung Cancer
Global LeaderStage IV
Stage III
Stage II
Top PIs
Timothy Wassenaar, MDUW Cancer Center at ProHealth Care5 years of reported clinical research
Expert in Cancer
Expert in Lung Cancer
111 reported clinical trials
188 drugs studied
Wingate F. ClapperProHealth Oconomowoc Memorial Hospital11 years of reported clinical research
Studies Breast Cancer
1 reported clinical trial
3 drugs studied
Clinical Trials running at ProHealth Waukesha Memorial Hospital
Breast Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Bladder Cancer
Bladder Carcinoma
Cancer
Gastroesophageal Junction Adenocarcinoma
Gastric Cancer
Esophageal Cancer
Cutaneous Melanoma
Support Program
for Breast Cancer
This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treatment for hormone receptor positive breast cancer patients. Adding text message reminders and/or telephone-based counseling to usual care may increase the number of days that patients take their endocrine therapy medication as prescribed.
Recruiting2 awards Phase 34 criteria
Chemotherapy Reduction After Surgery
for Breast Cancer
This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after pre-operative chemotherapy and HER2-targeted therapy. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Trastuzumab and pertuzumab are both a form of "targeted therapy" because they work by attaching themselves to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When these drugs attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Giving paclitaxel, trastuzumab, and pertuzumab may enable fewer chemotherapy drugs to be given without compromising patient outcomes compared to the usual treatment.
Recruiting1 award Phase 227 criteria
T-DM1 + Tucatinib
for Breast Cancer
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at ProHealth Waukesha Memorial Hospital?
ProHealth Waukesha Memorial Hospital is a medical facility located in Waukesha, Wisconsin. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Recurrence, Adenocarcinoma and other specialties. ProHealth Waukesha Memorial Hospital is involved with conducting 217 clinical trials across 300 conditions. There are 2 research doctors associated with this hospital, such as Timothy Wassenaar, MD and Wingate F. Clapper.